tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
UroGen Pharma reports Q3 EPS (69c), consensus (68c)
PremiumThe FlyUroGen Pharma reports Q3 EPS (69c), consensus (68c)
19d ago
UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
Premium
The Fly
UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
19d ago
UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment
Premium
Company Announcements
UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment
29d ago
Promising Developments and Market Potential Drive Buy Rating for Urogen Pharma’s Zusduri
PremiumRatingsPromising Developments and Market Potential Drive Buy Rating for Urogen Pharma’s Zusduri
2M ago
Citizens JMP healthcare analysts hold an analyst/industry conference call
Premium
The Fly
Citizens JMP healthcare analysts hold an analyst/industry conference call
2M ago
UroGen Pharma announces inducement grants under Nasdaq listing rule
Premium
The Fly
UroGen Pharma announces inducement grants under Nasdaq listing rule
3M ago
UroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
PremiumThe FlyUroGen Pharma price target lowered to $40 from $50 at H.C. Wainwright
4M ago
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
Premium
Company Announcements
UroGen Pharma Reports Q2 2025 Results and Launches ZUSDURI
4M ago
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
Premium
Ratings
Urogen Pharma’s Strategic Positioning and Growth Potential: Buy Rating Affirmed by Tara Bancroft
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100